Garrido A, Brunet S, Calabuig M, et al. Final results of the CETLAM LAM-203 trial fort he treatment of primary AML up tot the age of 70. EHA 2017, abstract S790.
Behandeling met emicizumab bij ernstige hemofilie alleen in basispakket na prijsdaling
feb 2020 | Benigne hematologie